benzylpenicillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2082 61-33-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • penicillin g
  • benzylpenicillin
  • benzylpenicillin G
  • free penicillin G
  • benzylpenicillinic acid
  • penicillin G potassium
  • penicillin
  • penicillin G sodium
  • benzylpenicillin potassium
  • benzylpenicillin sodium
A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065)
  • Molecular weight: 334.39
  • Formula: C16H18N2O4S
  • CLOGP: 1.75
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 86.71
  • ALOGS: -3.07
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3.60 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 564.67 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.24 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.40 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.70 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 2.68 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.306 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.138 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.771 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.877 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 69.270 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 50.230 % High 1
herg hERG pIC50 4.340 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.159 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 2.999 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 70.720 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 42
kinase-selectivity-class AXL,EIF2AK3,GRK2,MAP2K6 4
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.463 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.618 High 1
mh-clint Mouse hepatocyte intrinsic clearance 3.565 High 1
mppb Mouse plasma protein binding (% unbound) 67.730 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.574 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 51.730 % High 1
rat-kpuu-brain Rat brain Kpuu 0.007 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.503 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 84.480 % High 1
rppb Rat plasma protein binding (% unbound) 61.310 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 935.406 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 6, 1947 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1654.00 14.83 1007 14593 462602 90150245
Anaphylactic reaction 245.72 14.83 165 15435 87359 90525488
Loss of employment 226.20 14.83 60 15540 2927 90609920
Urticaria 163.26 14.83 233 15367 312501 90300346
Rash 157.02 14.83 390 15210 795710 89817137
Hepatic steatosis 139.35 14.83 84 15516 36861 90575986
Oesophageal spasm 121.65 14.83 38 15562 3323 90609524
Oesophageal pain 119.71 14.83 40 15560 4334 90608513
Lymphoedema 117.32 14.83 54 15546 13699 90599148
Hypersensitivity 81.14 14.83 215 15385 454462 90158385
Cough 73.57 14.83 182 15418 368780 90244067
Lipase increased 68.69 14.83 35 15565 11076 90601771
Sinobronchitis 67.25 14.83 17 15583 684 90612163
Cardiac failure congestive 65.79 14.83 83 15517 98611 90514236
Drug intolerance 62.64 14.83 194 15406 447397 90165450
Sleep apnoea syndrome 61.82 14.83 48 15552 31699 90581148
Abdominal pain upper 51.99 14.83 150 15450 332524 90280323
Hepatitis infectious mononucleosis 50.45 14.83 10 15590 128 90612719
Cardiac failure 46.15 14.83 74 15526 109422 90503425
Cystitis 45.87 14.83 57 15543 66661 90546186
Allergic sinusitis 44.92 14.83 16 15584 2097 90610750
Systemic lupus erythematosus 44.79 14.83 5 15595 361891 90250956
Glossodynia 43.73 14.83 3 15597 321776 90291071
Gastric disorder 43.40 14.83 40 15560 33344 90579503
Wound 40.66 14.83 3 15597 302977 90309870
Autoimmune thyroiditis 40.66 14.83 20 15580 5873 90606974
Pneumococcal infection 40.59 14.83 13 15587 1232 90611615
Eczema herpeticum 40.08 14.83 9 15591 216 90612631
Tinnitus 40.02 14.83 43 15557 43059 90569788
Pruritus 38.82 14.83 190 15410 541335 90071512
Hallucination 38.54 14.83 52 15548 65907 90546940
Toxic epidermal necrolysis 38.50 14.83 37 15563 32491 90580356
Infusion related reaction 38.40 14.83 12 15588 416768 90196079
Administration site bruise 33.28 14.83 9 15591 472 90612375
Bronchial obstruction 32.94 14.83 12 15588 1677 90611170
Lipoedema 31.20 14.83 8 15592 341 90612506
Agitation 30.55 14.83 47 15553 67051 90545796
Pancreatitis 30.53 14.83 48 15552 69778 90543069
Hand deformity 30.17 14.83 7 15593 296355 90316492
Alopecia 29.68 14.83 25 15575 495046 90117801
Joint swelling 28.27 14.83 27 15573 503273 90109574
Pericarditis 28.27 14.83 6 15594 270145 90342702
Confusional state 27.77 14.83 16 15584 386189 90226658
Angioedema 27.54 14.83 44 15556 64832 90548015
Idiosyncratic drug reaction 27.05 14.83 9 15591 962 90611885
Malaise 26.50 14.83 182 15418 585804 90027043
Fall 25.74 14.83 27 15573 481783 90131064
Feeling abnormal 25.67 14.83 75 15525 167160 90445687
Dysbiosis 25.60 14.83 10 15590 1692 90611155
Impaired healing 24.92 14.83 5 15595 234194 90378653
Cardiac septal defect 24.79 14.83 8 15592 777 90612070
Salpingo-oophorectomy bilateral 24.76 14.83 7 15593 433 90612414
Hypertension 24.28 14.83 148 15452 457384 90155463
Eczema 24.02 14.83 37 15563 52833 90560014
Administration site swelling 23.23 14.83 9 15591 1490 90611357
Type IV hypersensitivity reaction 23.20 14.83 12 15588 3914 90608933
Folliculitis 22.51 14.83 4 15596 204349 90408498
Fistula discharge 22.32 14.83 8 15592 1067 90611780
Tendon operation 21.89 14.83 6 15594 331 90612516
Anaemia neonatal 21.26 14.83 6 15594 369 90612478
Oligohydramnios 21.19 14.83 14 15586 7187 90605660
Upper limb fracture 20.86 14.83 22 15578 21556 90591291
Dyspnoea 20.71 14.83 237 15363 880718 89732129
Jarisch-Herxheimer reaction 20.36 14.83 6 15594 430 90612417
Nasal polyps 20.20 14.83 16 15584 10864 90601983
Prolonged rupture of membranes 19.98 14.83 4 15596 54 90612793
Phlebectomy 19.92 14.83 4 15596 55 90612792
Hypertrophic cardiomyopathy 19.79 14.83 9 15591 2219 90610628
Wrist surgery 19.50 14.83 7 15593 938 90611909
Foetal exposure during pregnancy 19.42 14.83 30 15570 42945 90569902
Spinal cord disorder 19.40 14.83 8 15592 1557 90611290
Blood cholesterol increased 19.12 14.83 6 15594 208006 90404841
Irritable bowel syndrome 19.04 14.83 6 15594 207442 90405405
Exposure to SARS-CoV-2 18.96 14.83 9 15591 2443 90610404
Death 18.82 14.83 31 15569 456520 90156327
Drug ineffective 18.77 14.83 338 15262 1383960 89228887
Exposure during pregnancy 18.73 14.83 86 15514 238324 90374523
Intentional product use issue 18.65 14.83 7 15593 216885 90395962
Drug reaction with eosinophilia and systemic symptoms 18.14 14.83 29 15571 42729 90570118
Limb discomfort 17.80 14.83 27 15573 38033 90574814
General physical health deterioration 17.74 14.83 21 15579 355094 90257753
Vision blurred 17.44 14.83 50 15550 110243 90502604
Bladder spasm 17.40 14.83 8 15592 2022 90610825
Carpal tunnel syndrome 17.34 14.83 21 15579 23907 90588940
Pharyngeal swelling 17.14 14.83 14 15586 9930 90602917
Periarthritis 17.14 14.83 9 15591 3028 90609819
Pharyngeal oedema 16.93 14.83 16 15584 13755 90599092
Type 2 diabetes mellitus 16.75 14.83 7 15593 203237 90409610
Musculoskeletal stiffness 16.52 14.83 16 15584 296516 90316331
Gonorrhoea 16.33 14.83 4 15596 141 90612706
Skin reaction 16.33 14.83 18 15582 18535 90594312
Urticaria contact 16.20 14.83 3 15597 26 90612821
Myelopathy 16.08 14.83 9 15591 3435 90609412
Gait inability 15.84 14.83 3 15597 146453 90466394
Ill-defined disorder 15.84 14.83 6 15594 184885 90427962
Poor venous access 15.57 14.83 18 15582 19509 90593338
Osteoporosis 15.49 14.83 44 15556 96487 90516360
Carcinogenicity 15.47 14.83 3 15597 34 90612813
Migraine 15.19 14.83 69 15531 190323 90422524
Diarrhoea 15.13 14.83 236 15364 938954 89673893
Animal scratch 15.02 14.83 7 15593 1823 90611024
Sputum discoloured 14.94 14.83 18 15582 20373 90592474

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 466.00 17.31 296 10348 99093 42511598
Spinal muscular atrophy 101.33 17.31 23 10621 393 42610298
Sleep disorder due to general medical condition, insomnia type 89.46 17.31 27 10617 1442 42609249
Rheumatoid arthritis 80.60 17.31 74 10570 42366 42568325
Pneumococcal sepsis 76.96 17.31 24 10620 1431 42609260
Antineutrophil cytoplasmic antibody positive 73.91 17.31 31 10613 4334 42606357
Acute generalised exanthematous pustulosis 70.55 17.31 37 10607 8558 42602133
Motor neurone disease 69.62 17.31 18 10626 541 42610150
Mite allergy 69.59 17.31 31 10613 5015 42605676
Dust allergy 67.95 17.31 31 10613 5301 42605390
Mycotic allergy 67.30 17.31 30 10614 4861 42605830
Cellulitis enterococcal 66.76 17.31 13 10631 100 42610591
Increased bronchial secretion 65.72 17.31 24 10620 2322 42608369
Conjunctivitis allergic 64.90 17.31 31 10613 5880 42604811
Stoma closure 64.18 17.31 15 10629 293 42610398
Total lung capacity abnormal 63.53 17.31 28 10616 4415 42606276
Neuritis 63.40 17.31 31 10613 6189 42604502
Oral surgery 63.21 17.31 17 10627 597 42610094
Respiratory tract infection bacterial 62.80 17.31 22 10622 1887 42608804
Spirometry abnormal 62.70 17.31 29 10615 5117 42605574
Sputum increased 62.19 17.31 25 10619 3138 42607553
Ischaemic cerebral infarction 62.07 17.31 21 10623 1622 42609069
Pulmonary vasculitis 60.21 17.31 30 10614 6236 42604455
Disease complication 59.44 17.31 24 10620 3046 42607645
Jarisch-Herxheimer reaction 58.69 17.31 17 10627 786 42609905
Oral disorder 58.26 17.31 27 10617 4785 42605906
Forced expiratory volume decreased 57.41 17.31 31 10613 7599 42603092
Bronchial disorder 57.30 17.31 19 10625 1379 42609312
Chest X-ray abnormal 56.79 17.31 26 10618 4482 42606209
Capillaritis 55.82 17.31 21 10623 2207 42608484
Normochromic normocytic anaemia 55.18 17.31 32 10612 8999 42601692
Neurological symptom 54.75 17.31 33 10611 9958 42600733
Eosinophilic granulomatosis with polyangiitis 53.82 17.31 31 10613 8607 42602084
Resuscitation 52.35 17.31 19 10625 1806 42608885
Lymphadenectomy 52.15 17.31 14 10630 488 42610203
Lower respiratory tract infection bacterial 50.54 17.31 14 10630 550 42610141
Nodule 50.27 17.31 34 10610 12500 42598191
Metabolic disorder 49.20 17.31 24 10620 4764 42605927
Respiratory symptom 49.07 17.31 32 10612 11074 42599617
Lung consolidation 44.38 17.31 25 10619 6652 42604039
Cerebral ischaemia 43.42 17.31 25 10619 6934 42603757
Brain injury 41.21 17.31 25 10619 7630 42603061
Sleep disorder due to a general medical condition 40.24 17.31 34 10610 17419 42593272
Arteriosclerosis 39.35 17.31 34 10610 17955 42592736
Scoliosis 39.28 17.31 18 10626 3108 42607583
Mesangioproliferative glomerulonephritis 39.10 17.31 9 10635 164 42610527
Intestinal ischaemia 38.93 17.31 26 10618 9362 42601329
Pulmonary alveolar haemorrhage 38.63 17.31 31 10613 14785 42595906
Motor dysfunction 37.29 17.31 24 10620 8122 42602569
Demyelination 37.20 17.31 18 10626 3511 42607180
Coombs positive haemolytic anaemia 35.95 17.31 13 10631 1222 42609469
Urticaria 35.31 17.31 65 10579 73971 42536720
Tachypnoea 33.95 17.31 34 10610 21628 42589063
Type IV hypersensitivity reaction 33.69 17.31 15 10629 2422 42608269
Middle insomnia 33.22 17.31 22 10622 7811 42602880
Chest discomfort 33.08 17.31 58 10586 63558 42547133
Vasculitis 32.82 17.31 31 10613 18363 42592328
Meningitis meningococcal 32.69 17.31 7 10637 90 42610601
Drug reaction with eosinophilia and systemic symptoms 32.49 17.31 46 10598 42029 42568662
Arteriosclerosis coronary artery 32.41 17.31 31 10613 18646 42592045
Muscle atrophy 31.91 17.31 22 10622 8339 42602352
Pulmonary fibrosis 31.43 17.31 36 10608 26645 42584046
Proteus infection 30.87 17.31 12 10632 1378 42609313
Ureterolithiasis 29.84 17.31 14 10630 2550 42608141
Obstructive airways disorder 28.48 17.31 33 10611 24726 42585965
Radiation fibrosis - lung 28.24 17.31 5 10639 21 42610670
Marrow hyperplasia 28.19 17.31 11 10633 1276 42609415
Atelectasis 27.81 17.31 29 10615 19332 42591359
Rheumatoid nodule 27.77 17.31 14 10630 2981 42607710
Lymphadenitis 27.05 17.31 13 10631 2498 42608193
Toxicity to various agents 26.58 17.31 12 10632 229124 42381567
Osteomyelitis salmonella 26.48 17.31 5 10639 32 42610659
Pain in jaw 25.03 17.31 24 10620 14478 42596213
Differential white blood cell count abnormal 24.96 17.31 11 10633 1733 42608958
Anaphylactic reaction 24.89 17.31 41 10603 42702 42567989
Myelofibrosis 24.36 17.31 11 10633 1836 42608855
Secretion discharge 24.33 17.31 18 10626 7617 42603074
Pleocytosis 23.17 17.31 8 10636 657 42610034
Clonal haematopoiesis 22.81 17.31 6 10638 193 42610498
Hypersensitivity 22.15 17.31 53 10591 72317 42538374
Spinal cord abscess 22.10 17.31 7 10637 439 42610252
Full blood count abnormal 22.08 17.31 32 10612 29844 42580847
Foetal heart rate increased 21.89 17.31 3 10641 0 42610691
Synovitis 21.79 17.31 23 10621 15544 42595147
Hypothyroidism 21.75 17.31 33 10611 32051 42578640
Drug intolerance 21.57 17.31 56 10588 80368 42530323
Splenic infarction 21.48 17.31 11 10633 2420 42608271
Injury 21.20 17.31 27 10617 22289 42588402
Condition aggravated 21.15 17.31 124 10520 260630 42350061
Biopsy liver 20.78 17.31 6 10638 274 42610417
Migraine with aura 20.64 17.31 8 10636 911 42609780
Sciatic nerve injury 19.82 17.31 5 10639 136 42610555
Endotracheal intubation 19.45 17.31 12 10632 3773 42606918
C-reactive protein decreased 19.42 17.31 10 10634 2226 42608465
Mechanical ventilation 19.24 17.31 10 10634 2267 42608424
Skin mass 19.15 17.31 13 10631 4803 42605888
Haemolysis 18.72 17.31 17 10627 9572 42601119
Circulatory collapse 18.47 17.31 26 10618 23610 42587081
Lung disorder 17.90 17.31 38 10606 47885 42562806
Meningitis aseptic 17.59 17.31 12 10632 4470 42606221

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1067.77 15.04 804 20835 453286 110114374
Loss of employment 216.38 15.04 61 21578 3283 110564377
Anaphylactic reaction 187.58 15.04 165 21474 114135 110453525
Hepatic steatosis 132.92 15.04 95 21544 48736 110518924
Oesophageal spasm 125.63 15.04 41 21598 3625 110564035
Oesophageal pain 119.66 15.04 43 21596 5082 110562578
Lymphoedema 106.50 15.04 54 21585 14875 110552785
Urticaria 101.73 15.04 205 21434 318652 110249008
Spinal muscular atrophy 100.71 15.04 22 21617 405 110567255
Rash 96.19 15.04 365 21274 820599 109747061
Pneumococcal sepsis 76.85 15.04 25 21614 2187 110565473
Antineutrophil cytoplasmic antibody positive 76.68 15.04 31 21608 5045 110562615
Mite allergy 72.67 15.04 31 21608 5772 110561888
Dust allergy 71.67 15.04 31 21608 5970 110561690
Motor neurone disease 69.35 15.04 18 21621 706 110566954
Total lung capacity abnormal 69.27 15.04 28 21611 4555 110563105
Mycotic allergy 68.64 15.04 30 21609 5924 110561736
Spirometry abnormal 67.63 15.04 29 21610 5468 110562192
Conjunctivitis allergic 67.39 15.04 31 21608 6900 110560760
Forced expiratory volume decreased 66.85 15.04 38 21601 13138 110554522
Sinobronchitis 66.24 15.04 16 21623 466 110567194
Pulmonary vasculitis 65.85 15.04 30 21609 6530 110561130
Neuritis 65.45 15.04 31 21608 7368 110560292
Stoma closure 63.16 15.04 15 21624 406 110567254
Respiratory tract infection bacterial 59.15 15.04 21 21618 2395 110565265
Capillaritis 58.96 15.04 21 21618 2418 110565242
Type IV hypersensitivity reaction 58.70 15.04 27 21612 6006 110561654
Increased bronchial secretion 55.84 15.04 23 21616 3925 110563735
Ischaemic cerebral infarction 55.10 15.04 21 21618 2924 110564736
Eosinophilic granulomatosis with polyangiitis 54.70 15.04 31 21608 10655 110557005
Acute generalised exanthematous pustulosis 54.05 15.04 40 21599 21624 110546036
Sleep apnoea syndrome 53.85 15.04 52 21587 40395 110527265
Chest X-ray abnormal 52.78 15.04 28 21611 8459 110559201
Oral surgery 52.57 15.04 17 21622 1459 110566201
Sputum increased 50.58 15.04 24 21615 5727 110561933
Disease complication 50.28 15.04 24 21615 5803 110561857
Drug intolerance 50.11 15.04 184 21455 406328 110161332
Drug reaction with eosinophilia and systemic symptoms 49.17 15.04 70 21569 82025 110485635
Bronchial disorder 49.09 15.04 19 21620 2757 110564903
Normochromic normocytic anaemia 48.95 15.04 31 21608 13026 110554634
Cough 48.78 15.04 199 21440 461442 110106218
Mesangioproliferative glomerulonephritis 48.19 15.04 11 21628 249 110567411
Resuscitation 48.08 15.04 19 21620 2914 110564746
Respiratory symptom 47.51 15.04 32 21607 14913 110552747
Jarisch-Herxheimer reaction 47.39 15.04 15 21624 1202 110566458
Neurological symptom 46.25 15.04 32 21607 15576 110552084
Toxic epidermal necrolysis 45.78 15.04 56 21583 56671 110510989
Allergic sinusitis 45.58 15.04 16 21623 1765 110565895
Abdominal pain upper 45.54 15.04 161 21478 348950 110218710
Lower respiratory tract infection bacterial 44.86 15.04 14 21625 1071 110566589
Hepatitis infectious mononucleosis 44.26 15.04 10 21629 216 110567444
Joint swelling 42.08 15.04 17 21622 442828 110124832
Cystitis 40.56 15.04 57 21582 65979 110501681
Lymphadenectomy 40.08 15.04 14 21625 1522 110566138
Lung consolidation 39.59 15.04 25 21614 10451 110557209
Meningitis meningococcal 39.21 15.04 9 21630 209 110567451
Oral disorder 38.87 15.04 26 21613 11977 110555683
Cellulitis enterococcal 38.61 15.04 7 21632 46 110567614
Administration site bruise 38.50 15.04 9 21630 227 110567433
Malaise 37.43 15.04 242 21397 671577 109896083
Gastric disorder 37.27 15.04 39 21600 33318 110534342
Arteriosclerosis 37.10 15.04 34 21605 24733 110542927
Pulmonary alveolar haemorrhage 36.89 15.04 31 21608 20119 110547541
Autoimmune thyroiditis 36.58 15.04 20 21619 6414 110561246
Completed suicide 36.19 15.04 3 21636 242378 110325282
Fall 36.02 15.04 39 21600 603443 109964217
Coombs positive haemolytic anaemia 35.94 15.04 13 21626 1564 110566096
Cardiac failure congestive 35.50 15.04 86 21553 150914 110416746
Tachypnoea 35.26 15.04 41 21598 39354 110528306
Wound 34.73 15.04 3 21636 234434 110333226
Metabolic disorder 34.60 15.04 23 21616 10487 110557173
Pneumococcal infection 34.13 15.04 13 21626 1806 110565854
Cerebral ischaemia 33.96 15.04 24 21615 12080 110555580
Brain injury 33.88 15.04 25 21614 13451 110554209
Hypersensitivity 33.45 15.04 162 21477 403836 110163824
Alopecia 33.05 15.04 15 21624 364738 110202922
Arteriosclerosis coronary artery 32.88 15.04 32 21607 25086 110542574
Nodule 32.67 15.04 36 21603 32595 110535065
Drug ineffective 32.59 15.04 446 21193 1520094 109047566
Angioedema 32.13 15.04 64 21575 98436 110469224
Eczema herpeticum 32.05 15.04 9 21630 477 110567183
Intestinal ischaemia 31.93 15.04 26 21613 16153 110551507
Systemic lupus erythematosus 31.12 15.04 6 21633 254332 110313328
Salpingo-oophorectomy bilateral 30.84 15.04 8 21631 313 110567347
Toxicity to various agents 29.85 15.04 30 21609 480525 110087135
Administration site swelling 29.73 15.04 9 21630 622 110567038
Tinnitus 29.65 15.04 47 21592 60493 110507167
Productive cough 28.92 15.04 67 21572 114238 110453422
Full blood count abnormal 28.12 15.04 44 21595 56008 110511652
Marrow hyperplasia 27.23 15.04 11 21628 1785 110565875
Haemolysis 26.46 15.04 23 21616 15616 110552044
Scoliosis 26.10 15.04 18 21621 8715 110558945
Ureterolithiasis 25.90 15.04 14 21625 4388 110563272
Osteomyelitis salmonella 25.90 15.04 5 21634 48 110567612
Hand deformity 25.00 15.04 6 21633 218500 110349160
Demyelination 24.85 15.04 18 21621 9411 110558249
Differential white blood cell count abnormal 24.69 15.04 11 21628 2273 110565387
Bronchial obstruction 24.51 15.04 12 21627 3067 110564593
Hallucination 24.08 15.04 58 21581 101374 110466286
Haemoptysis 24.04 15.04 47 21592 71307 110496353
Muscle atrophy 23.46 15.04 20 21619 13234 110554426
Radiation fibrosis - lung 23.15 15.04 5 21634 87 110567573
Confusional state 23.07 15.04 35 21604 468645 110099015
Anxiety 22.77 15.04 130 21509 344948 110222712
Product administered to patient of inappropriate age 22.70 15.04 16 21623 8020 110559640
Chest discomfort 22.48 15.04 80 21559 173768 110393892
Pruritus 22.37 15.04 192 21447 581368 109986292
Sleep disorder due to a general medical condition 22.20 15.04 38 21601 52074 110515586
Vasculitis 22.08 15.04 31 21608 35842 110531818
Idiosyncratic drug reaction 21.90 15.04 9 21630 1527 110566133
Therapeutic product effect decreased 21.67 15.04 100 21539 244216 110323444
General physical health deterioration 21.67 15.04 31 21608 425264 110142396
Myelofibrosis 21.65 15.04 11 21628 3040 110564620
Rash maculo-papular 21.58 15.04 46 21593 74176 110493484
Obstructive airways disorder 21.46 15.04 35 21604 46114 110521546
Migraine 21.35 15.04 78 21561 171574 110396086
Spinal cord abscess 21.09 15.04 7 21632 652 110567008
Pleocytosis 20.89 15.04 9 21630 1715 110565945
Contraindicated product administered 20.84 15.04 100 21539 248167 110319493
Splenic infarction 20.55 15.04 12 21627 4362 110563298
Lymphadenitis 20.49 15.04 13 21626 5480 110562180
Folliculitis 20.41 15.04 4 21635 167649 110400011
Hypoaesthesia 20.21 15.04 19 21620 314204 110253456
Dyspnoea 20.19 15.04 316 21323 1106556 109461104
Type 2 diabetes mellitus 20.02 15.04 5 21634 177227 110390433
Cardiac failure 19.86 15.04 81 21558 187545 110380115
Pericarditis 19.85 15.04 9 21630 219105 110348555
Irritable bowel syndrome 19.82 15.04 4 21635 164211 110403449
Prolonged rupture of membranes 19.54 15.04 4 21635 53 110567607
Blood cholesterol increased 19.40 15.04 6 21633 184779 110382881
C-reactive protein decreased 19.23 15.04 10 21629 2899 110564761
Circulatory collapse 19.18 15.04 32 21607 42961 110524699
Dysbiosis 19.06 15.04 9 21630 2123 110565537
Type I hypersensitivity 18.69 15.04 13 21626 6380 110561280
Ectopic pregnancy 18.42 15.04 9 21630 2288 110565372
Lipoedema 18.21 15.04 5 21634 244 110567416
Agitation 18.16 15.04 56 21583 112995 110454665
Mechanical ventilation 18.03 15.04 10 21629 3297 110564363
Motor dysfunction 17.94 15.04 23 21616 24383 110543277
Malignant neoplasm progression 17.74 15.04 6 21633 174561 110393099
Decreased appetite 17.73 15.04 42 21597 475804 110091856
Vaccination failure 17.68 15.04 9 21630 2497 110565163
Upper limb fracture 17.46 15.04 21 21618 20867 110546793
Atelectasis 17.29 15.04 28 21611 36684 110530976
Biopsy liver 17.22 15.04 6 21633 647 110567013
Tendon operation 17.20 15.04 5 21634 300 110567360
Gait inability 17.14 15.04 3 21636 136373 110431287
Endotracheal intubation 16.81 15.04 12 21627 6132 110561528
Hypothyroidism 16.57 15.04 41 21598 72858 110494802
Bone density abnormal 16.49 15.04 10 21629 3893 110563767
Infusion related reaction 16.41 15.04 31 21608 381131 110186529
Periarthritis 16.38 15.04 10 21629 3940 110563720
Vision blurred 16.36 15.04 59 21580 128963 110438697
Urticaria contact 15.82 15.04 3 21636 26 110567634
Erysipelas 15.81 15.04 16 21623 13142 110554518
Nasal polyps 15.77 15.04 16 21623 13184 110554476
Drug resistance 15.32 15.04 34 21605 56340 110511320
Leukocytosis 15.23 15.04 33 21606 53795 110513865

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CE01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Beta-lactamase sensitive penicillins
ATC S01AA14 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antibiotics
FDA CS M0016152 Penicillins
FDA EPC N0000175497 Penicillin-class Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50904 allergen
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:53000 epitope
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:88188 drug allergen

Related Drugs by ATC class:

J01CE Beta-lactamase sensitive penicillins 9 drugs
azidocillinbenzathine benzylpenicillinbenzathine phenoxymethylpenicillinclometocillinpenamecillinpheneticillinphenoxymethylpenicillinprocaine benzylpenicillinpropicillin
S01AA Antibiotics 27 drugs
amikacinampicillinazidamfenicolazithromycinbacitracincefmenoximecefuroximechloramphenicolchlortetracyclinedibekacindihydrostreptomycinerythromycin show all 27 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Rat bite fever indication 1685005
Acute otitis media indication 3110003
Meningococcemia indication 4089001
Streptococcal meningitis indication 4510004 DOID:11574
Gangrenous pneumonia indication 7063008
Inhalational anthrax indication 11389007
Actinomycotic infection indication 11817007 DOID:8478
Anthrax septicemia indication 14972006
Infection of skin AND/OR subcutaneous tissue indication 19824006
Gingivostomatitis indication 20607006
Pulmonary actinomycosis indication 21846001
Pinta indication 22064009 DOID:1022
Cervicofacial actinomycosis indication 23014006
Neurosyphilis indication 26039008 DOID:9988
Gonococcal conjunctivitis neonatorum indication 28438004
Scarlet fever indication 30242009 DOID:8596
Listeria meningitis indication 31568009 DOID:11572
Pneumonia due to Streptococcus indication 34020007
Congenital syphilis indication 35742006 DOID:9856
Streptococcal tonsillitis indication 41582007
Abdominal actinomycosis indication 43894001
Erysipelas indication 44653001 DOID:11330
Gonococcal infection of joint indication 44743006
Pneumococcal meningitis indication 51169003
Upper respiratory infection indication 54150009
Yaws indication 70647001 DOID:10371
Late syphilis indication 72083004 DOID:8200
Abscess of lung indication 73452002 DOID:0060317
Syphilis indication 76272004
Tetanus indication 76902006 DOID:11338
Pasteurella infection indication 83172007 DOID:11055
Cutaneous anthrax indication 84980006 DOID:7426
Streptococcal infectious disease indication 85769006
Tertiary lesion of yaws indication 88037009
Gastrointestinal anthrax indication 111798006 DOID:13386
Listerial endocarditis indication 186318004
Primary genital syphilis indication 186847001
Latent early syphilis indication 186867005
Late latent syphilis indication 186903006
Latent yaws indication 186973005
Meningococcal meningitis indication 192644005
Infection by Pasteurella multocida indication 197718007
Sepsis of the newborn indication 206376005
Pneumococcal pneumonia indication 233607000
Neonatal pneumonia indication 233619008
Streptococcal toxic shock syndrome indication 240451000
Secondary syphilis indication 240557004 DOID:4157
Bejel indication 240686008 DOID:13431
Gas gangrene caused by clostridium perfringens indication 266093005
Neonatal meningitis indication 276674008
Bacterial endocarditis indication 301183007
Streptococcus pyogenes infection indication 302809008
Septicemia due to enterococcus indication 310669007
Infective otitis media indication 312218008
Diphtheria indication 397428000
Infection due to Clostridium botulinum indication 398565003
Fusospirochetal pharyngitis indication 399095008
Erysipeloid indication 400105005
Pharyngitis indication 405737000 DOID:2275
Infection due to Staphylococcus aureus indication 406602003
Anthrax indication 409498004 DOID:7427
Aspiration pneumonia indication 422588002 DOID:3240
Latent syphilis indication 444150000 DOID:9531
Streptococcus Myositis indication
Disseminated Gonococcal Infection indication
Tertiary Bejel indication
Pneumococcal Acute Otitis Media indication
Necrotizing Fasciitis Streptococcus Infection indication
Upper Respiratory Infection due to Neisseria Meningitidis indication
Streptococcus Empyema indication
Pneumococcus Endocarditis indication
Streptococcal Endocarditis indication
Upper Respiratory Pneumococcal Infection indication
Latent Bejel indication
Upper Respiratory Streptococcal Infection indication
Streptococcus Pericarditis indication
Rheumatic Fever Prevention indication
Clostridium Perfringens Empyema indication
Neonatal Group B Streptococcal Septicemia indication
Asymptomatic Congenital Syphilis indication
Granulomatosis Infantiseptica indication
Infection Prevention from Tooth Extraction indication
Lyme disease off-label use 23502006 DOID:11729
Lyme arthritis off-label use 33937009
Neonatal conjunctivitis off-label use 34298002 DOID:9699
Omphalitis of the newborn off-label use 42052009
Lyme carditis off-label use 77863005
Relapsing fever off-label use 420079008 DOID:13034
Infection due to anaerobic bacteria off-label use 423451008
Pneumococcal Infection Prevention in Sickle Cell Disease off-label use
Lyme Disease of the Central Nervous System off-label use
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats No Use Class Stated Or Implied Indication
Dogs No Use Class Stated Or Implied Indication
Turkeys Erysipelas caused by Erysipelothrix rhusiopathiae Indication

🐶 Veterinary products

ProductApplicantIngredients
Penicillin G Potassium, USP Zoetis Inc. 1
Veesyn Granules for Oral Soln Boehringer lngelheim Animal Health USA Inc. 1
PenAqua Sol-G, Penicillin G Potassium, USP Bimeda Animal Health Limited 1
R-Pen Huvepharma EOOD 1
Solu-Pen Zoetis Inc. 1
Penicillin G Potassium USP Quo Vademus LLC 1
Han-Pen HQ Specialty Pharma Corp. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK
Beta-lactamase TEM Enzyme Ki 4.70 CHEMBL
Beta-lactamase Enzyme IC50 5.44 CHEMBL

External reference:

IDSource
4017440 VUID
N0000145828 NUI
D01053 KEGG_DRUG
113-98-4 SECONDARY_CAS_RN
69-57-8 SECONDARY_CAS_RN
4017435 VANDF
4017438 VANDF
4017440 VANDF
4019880 VANDF
C0030827 UMLSCUI
CHEBI:18208 CHEBI
PNN PDB_CHEM_ID
CHEMBL29 ChEMBL_ID
DB01053 DRUGBANK_ID
CHEMBL1223 ChEMBL_ID
CHEMBL1126 ChEMBL_ID
5904 PUBCHEM_CID
203133 RXNORM
179173 MMSL
179425 MMSL
2147 MMSL
2169 MMSL
5245 MMSL
5247 MMSL
d00116 MMSL
d07728 MMSL
d07729 MMSL
002679 NDDF
002680 NDDF
004977 NDDF
016121 NDDF
11986009 SNOMEDCT_US
323389000 SNOMEDCT_US
764146007 SNOMEDCT_US
78507004 SNOMEDCT_US
89055006 SNOMEDCT_US
D010400 MESH_DESCRIPTOR_UI
D010406 MESH_DESCRIPTOR_UI
4796 IUPHAR_LIGAND_ID
58 INN_ID
Q42T66VG0C UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Pfizerpen HUMAN PRESCRIPTION DRUG LABEL 1 0049-0420 POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 26 sections
Pfizerpen HUMAN PRESCRIPTION DRUG LABEL 1 0049-0430 POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 26 sections
Pfizerpen HUMAN PRESCRIPTION DRUG LABEL 1 0049-0520 POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 25 sections
Pfizerpen HUMAN PRESCRIPTION DRUG LABEL 1 0049-0520 POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 25 sections
Pfizerpen HUMAN PRESCRIPTION DRUG LABEL 1 0049-0530 POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 25 sections
Pfizerpen HUMAN PRESCRIPTION DRUG LABEL 1 0049-0530 POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 25 sections
PENICILLIN G POTASSIUM HUMAN PRESCRIPTION DRUG LABEL 1 0338-1021 INJECTION, SOLUTION 1000000 [iU] INTRAVENOUS NDA 23 sections
PENICILLIN G POTASSIUM HUMAN PRESCRIPTION DRUG LABEL 1 0338-1023 INJECTION, SOLUTION 2000000 [iU] INTRAVENOUS NDA 23 sections
PENICILLIN G POTASSIUM HUMAN PRESCRIPTION DRUG LABEL 1 0338-1025 INJECTION, SOLUTION 3000000 [iU] INTRAVENOUS NDA 23 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0781-6135 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 22 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 0781-6136 INJECTION, POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 22 sections
Penicillin G Sodium HUMAN PRESCRIPTION DRUG LABEL 1 0781-6153 INJECTION, POWDER, FOR SOLUTION 5000000 [USPU] INTRAMUSCULAR ANDA 23 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 25021-153 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 26 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 25021-154 INJECTION, POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 26 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 44567-310 INJECTION, POWDER, FOR SOLUTION 1000000 [iU] INTRAVENOUS ANDA 24 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 44567-311 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 24 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 44567-312 INJECTION, POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 24 sections
BUFFERED PENICILLIN G POTASSIUM HUMAN PRESCRIPTION DRUG LABEL 1 51662-1436 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAMUSCULAR ANDA 13 sections
PENICILLIN G POTASSIUM HUMAN PRESCRIPTION DRUG LABEL 1 51662-1689 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 11 sections
PENICILLIN G POTASSIUM HUMAN PRESCRIPTION DRUG LABEL 1 51662-1709 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAMUSCULAR ANDA 12 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 70860-126 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAMUSCULAR ANDA 25 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 70860-127 INJECTION, POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 25 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 72603-210 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 24 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 72603-345 INJECTION, POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 24 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 83634-102 INJECTION, POWDER, FOR SOLUTION 5000000 [iU] INTRAVENOUS ANDA 26 sections
Penicillin G Potassium HUMAN PRESCRIPTION DRUG LABEL 1 83634-103 INJECTION, POWDER, FOR SOLUTION 20000000 [iU] INTRAVENOUS ANDA 26 sections